Skip to main content

Breadcrumb

  1. Home

Submission Tool and Repository Measure Database

As the Centers for Medicare & Medicaid Services (CMS) consensus-based entity (CBE), Battelle Memorial Institute (Battelle) discloses complete information (e.g., full measure specifications, coding logic, algorithms) regarding each measure to the public for the purpose of evaluating, analyzing, or displaying of each measure for endorsement consideration. If an interested party wishes to attain complete measure information for the use and/or implementation of a measure, the interested party should contact the measure steward. Contact information for the measure steward can be found under the “Point of Contact” section of the respective." measure page within the Submission Tool and Repository (STAR). Battelle is not responsible for, nor is privy to the measure use agreements that may be established between a measure steward and an interested party.
No Filters Selected
          For the filters below, open and close each one at a time for the best experience
          CBE ID Title Steward Sort descending Endorsement Cycle Status Date of Last Endorsement Decision
          0694 Hospital Risk-Standardized Complication Rate Following Implantation of Implantable Cardioverter-Defibrillator (ICD) Endorsement Removed
          0695 Hospital 30-Day Risk-Standardized Readmission Rates following Percutaneous Coronary Intervention (PCI) Endorsement Removed
          1662 Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Endorsed with Conditions
          0384 Oncology: Medical and Radiation – Pain Intensity Quantified Endorsed with Conditions
          0384e Oncology: Medical and Radiation – Pain Intensity Quantified Endorsed with Conditions
          0383 Oncology: Medical and Radiation – Plan of Care for Pain Endorsed
          0219 Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer American College of Surgeons Endorsed
          0220 Adjuvant hormonal therapy is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or Stage IB – Stage III hormone receptor positive breast cancer American College of Surgeons Endorsed
          1741 Consumer Assessment of Healthcare Providers and Systems (CAHPS)® Surgical Care Survey Version 2.0 American College of Surgeons Endorsed
          0221 Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection American College of Surgeons Endorsement Removed